"VIPREG2024 1xbet free promo code 2024 Papua New Guinea"

Costs of new cancer treatments have grown exponentially and patients are treated longer with more agents, increasing the economic burden for patients and families, health care systems, and countries. The economic burden of cancer also includes indirect costs, measured as productivity losses from cancer morbidity and premature mortality, and productivity1

The IARC Monographs identify the causes of human cancer. Sometimes called the World Health Organization’s “Encyclopedia of Carcinogens,” the IARC Monographs are systematic evaluations of the strength of evidence that an agent can cause cancer in humans. Since the program’s inception in 1971, over 1,040 agents have been evaluated, including1

Global cancer control requires a coordinated response from national governments, researchers, funders, practitioners, advocates, patients, and international organizations. Multiple high-level resolutions have called for reduced cancer mortality, but work remains to meet targets and understand what approaches work best, especially in low- and middle-income countries (LMICs), where burden is increasing.1